Mastery In The MDL: Limiting FDA Regulatory Expert Opinion
Law360, New York (February 3, 2016, 12:43 PM EST) -- James D. Herschlein
Bert L. Slonim
This is the fourth of a series of five articles outlining litigation strategies for debunking Daubert expert testimony and explores ways to limit or exclude U.S. Food and Drug Administration expert testimony. Read previous parts here. A link to the original report is here.
It has become increasingly commonplace in pharmaceutical or medical device product liability litigation — particularly large, centralized mass tort litigations involving hundreds or thousands of plaintiffs — for both plaintiffs and defendants to offer competing FDA regulatory experts. As with all other expert testimony, FDA regulatory experts are permitted to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!